Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

Amgen plans to file regulatory applications for Uplizna in myasthenia gravis in the first half of 2025, while an application for IgG4-related disease is under priority review, with the FDA ...

Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...

Amgen has reported positive phase 3 results ... for additional indications on Soliris' label like generalised myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).

But Amgen’s move could make this far more difficult should it get a biosimilar approved in time, to treat rare diseases related to the complement system such as generalised myasthenia gravis ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...